UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000030782 |
|---|---|
| Receipt number | R000035143 |
| Scientific Title | Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously untreated or treated PD-L1 positive advanced non-small cell lung cancer |
| Date of disclosure of the study information | 2018/01/12 |
| Last modified on | 2019/03/22 12:13:29 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2018/01/12 11:14:26 | ||
| 2 | Update | 2019/03/22 12:09:02 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 3 | Update | 2019/03/22 12:10:43 | Date of IRB Last follow-up date |
|
| 4 | Update | 2019/03/22 12:11:41 | Public title Public title Scientific Title |
|
| 5 | Update | 2019/03/22 12:12:22 | Narrative objectives1 Narrative objectives1 |
|
| 6 | Update | 2019/03/22 12:13:29 | Interventions/Control_1 Interventions/Control_1 Key inclusion criteria Key inclusion criteria |
